Studies n | Sensitivity (95% CI) % | I2 % | p-value | Specificity (95% CI) % | I2 % | p-value | |
Urine preparation# | |||||||
Fresh¶ | 3 | 59 (53–64) | 95.4 | <0.0001 | 89 (85–92) | 0.0 | 0.9 |
Frozen | 6 | 49 (22–77) | 97.3 | <0.0001 | 97 (89–99) | 93.3 | <0.0001 |
Test version | |||||||
Noncommercial¶ | 2 | 82 (76–88) | 39.8 | 0.2 | 87 (85–89) | 62.3 | 0.1 |
Chemogen+ | 5 | 45 (26–66) | 95.1 | <0.0001 | 94 (82–98) | 88.9 | <0.0001 |
Alere¶,§ | 2 | 40 (35–46) | 98.7 | <0.0001 | 98 (95–99) | 61.6 | 0.1 |
Estimates were calculated using bivariate random effects models, preferentially using data excluding clinical cases (analysis A), otherwise using strict microbiological reference standards (analysis B). I2: inconsistency. #: if urine was frozen before lipoarabinomannan testing was performed, it was considered “frozen” whether processing of urine was done before or after freezing; ¶: univariate random effects regression performed because too few studies to converge bivariate model; +: Chemogen Inc., Portland, ME, USA; §: Alere Inc. (formerly Inverness Medical Innovations Inc.), Waltham, MA, USA.